Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma

BACKGROUND: Checkpoint-blockade immunotherapy targeting programmed cell death protein 1 (PD-1) has recently shown promising efficacy in hepatocellular carcinoma (HCC). However, the factors affecting and predicting the response to anti-PD-1 immunotherapy in HCC are still unclear. Herein, we report th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yi, Wang, Tingting, Tu, Xiaoxuan, Huang, Yun, Zhang, Hangyu, Tan, Di, Jiang, Weiqin, Cai, Shunfeng, Zhao, Peng, Song, Ruixue, Li, Peilu, Qin, Nan, Fang, Weijia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651993/
https://www.ncbi.nlm.nih.gov/pubmed/31337439
http://dx.doi.org/10.1186/s40425-019-0650-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651993/
https://www.ncbi.nlm.nih.gov/pubmed/31337439
http://dx.doi.org/10.1186/s40425-019-0650-9

Ejemplares similares